Wegovy is approved for chronic weight management in obesity or overweight with comorbidities, and as of March 2024, for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight
Also know what the side effects are
Guo H, Yang J, Huang J, Xu L, Lv Y, Wang Y, Ren J, Feng Y, Zheng Q, Li L
doi: 10.1159/000541615 16 GiudiceLOskotskyTFalakoSOpoku-AnaneJSirotaM
Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: A comprehensive review and meta-analysis
Based on the available information, the 2024 AHA Guideline for the Primary Prevention of Stroke recommends using GLP1RAs in patients with diabetes and high cardiovascular risk or established CVD and hemoglobin A1c 7% (Class of Recommendation 1, Level of Evidence A) [36]